As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

Loosely regulated online platforms are promoting powerful obesity shots as a universal weight-loss solution. Photographer: ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...

The recent stock weakness has a clear and powerful trigger. Novo Nordisk has dramatically slashed prices for its blockbuster drugs, Wegovy and Ozempic. The monthly cost for patients will drop from ...

KYIV () -A leading Ukrainian drone and missile manufacturer said on Monday that it has ​named former U. Secretary of State ...

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

Over half of people who started using semaglutide (Wegovy) for weight loss ditched it within the first 12 months, a Danish population-based study found. Among 77,310 adults without diabetes who began ...